{
    "2021-03-06": [
        [
            {
                "time": "",
                "original_text": "【浙商|孙建】药明康德：CDMO加速验证，2021年仍可期",
                "features": {
                    "keywords": [
                        "药明康德",
                        "CDMO",
                        "加速验证",
                        "2021年"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "近八成个股上涨，各类\"茅\"跌3.4万亿，后市操作指南来了…",
                "features": {
                    "keywords": [
                        "个股上涨",
                        "茅指数",
                        "下跌",
                        "后市操作"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "消费",
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "基因测序一周风云榜：药明康德市值大缩水，金域医学两股东三个月减持477万股 减持股份",
                "features": {
                    "keywords": [
                        "基因测序",
                        "药明康德",
                        "市值缩水",
                        "金域医学",
                        "减持"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "药明康德(603259)2020年业绩快报点评：CDMO加速验证 2021年仍可期",
                "features": {
                    "keywords": [
                        "药明康德",
                        "2020年业绩",
                        "CDMO",
                        "加速验证",
                        "2021年"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}